{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:40:15Z","timestamp":1790959215227,"version":"4.1.0"},"reference-count":55,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Center for Advancing Translational Sciences of the National Institutes of Health","award":["UL1TR001409"],"award-info":[{"award-number":["UL1TR001409"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the emerging success of treating CD19 expressing B cell malignancies with <jats:italic>ex vivo<\/jats:italic> modified, autologous T cells that express CD19\u2010directed chimeric antigen receptors (CAR), there is intense interest in expanding this evolving technology to develop effective modalities to treat other malignancies including solid tumors. Exploiting this approach to develop a therapeutic modality for T cell malignancies for which the available regimens are neither curative, nor confer long term survival we generated a lentivirus\u2010based CAR gene transfer system to target the chemokine receptor CCR4 that is over\u2010expressed in a spectrum of T cell malignancies as well as in CD4<jats:sup>+<\/jats:sup>CD25<jats:sup>+<\/jats:sup>Foxp3<jats:sup>+<\/jats:sup>T regulatory cells that accumulate in the tumor microenvironment constituting a barrier against anti\u2010tumor immunity. <jats:italic>Ex vivo<\/jats:italic> modified, donor\u2010derived T cells that expressed CCR4 directed CAR displayed antigen\u2010dependent potent cytotoxicity against patient\u2010derived cell lines representing ATL, CTCL, ALCL and a subset of HDL. Furthermore, these CAR T cells also eradicated leukemia in a mouse xenograft model of ATL illustrating the potential utility of this modality in the treatment of a wide spectrum of T cell malignancies.<\/jats:p>","DOI":"10.1002\/ajh.24794","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T21:55:26Z","timestamp":1495576526000},"page":"892-901","source":"Crossref","is-referenced-by-count":85,"title":["Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T\u2010cell malignancies"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6316-8618","authenticated-orcid":false,"given":"Liyanage P.","family":"Perera","sequence":"first","affiliation":[{"name":"Lymphoid Malignancies Branch, National Cancer Institute Bethesda Maryland 20892\u20101374 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, National Cancer Institute Bethesda Maryland 20892\u20101374 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, National Cancer Institute Bethesda Maryland 20892\u20101374 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Petrus","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, National Cancer Institute Bethesda Maryland 20892\u20101374 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyuki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Institute for Virus Research, Kyoto University Sakyo\u2010ku Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall E.","family":"Kadin","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine, Department of Dermatology and Skin Surgery Roger Williams Medical Center Providence Rhode 02908"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, National Cancer Institute Bethesda Maryland 20892\u20101374 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin\u2010Yu","family":"Perera","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center Washington D.C. 20422 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu079"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.05.018"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4488"},{"issue":"10","key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.4049\/jimmunol.161.10.5111","article-title":"Selective up\u2010regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells","volume":"161","author":"D'Ambrosio D","year":"1998","journal-title":"J Immunol."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1467"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070663"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.13.4046"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(00)00402-3"},{"issue":"9","key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.4049\/jimmunol.161.9.5027","article-title":"STCP\u20101 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL\u20104 and IL\u201013","volume":"161","author":"Andrew DP","year":"1998","journal-title":"J Immunol."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.3.1764"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80165-X"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2360"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27759"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120059"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2009.01029.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0261"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27966"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1505"},{"issue":"10","key":"e_1_2_7_21_1","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T\u2010cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida T","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP09OTJOYAVZZK"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.132"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000021006.53593.B0"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544809"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536359"},{"key":"e_1_2_7_27_1","volume-title":"International Classification of Diseases for Oncology (ICD\u2010O\u20103)","author":"Percy C","year":"2000"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/11631090-000000000-00000"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-600924"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1316796110"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0830"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0278"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140987"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-29"},{"issue":"24","key":"e_1_2_7_36_1","first-page":"6977","article-title":"IL\u20102R alpha\u2010Directed monoclonal antibodies provide effective therapy in a murine model of adult T\u2010cell leukemia by a mechanism other than blockade of IL\u20102\/IL\u20102R alpha interaction","volume":"60","author":"Phillips KE","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.11.021"},{"issue":"4","key":"e_1_2_7_38_1","first-page":"371","article-title":"Antigen\u2010Specific T\u2010Cell Activation Independently of the MHC: Chimeric Antigen Receptor\u2010Redirected T Cells","volume":"11","author":"Chmielewski M","year":"2013","journal-title":"Front Immunol."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.02.009"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2660"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.7.3542"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3356"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3444"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3415"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-131185"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-504308"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.4699"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210984"},{"issue":"4","key":"e_1_2_7_50_1","first-page":"1367","article-title":"Expression and function of FRA2\/JUND in cutaneous T\u2010cell lymphomas","volume":"32","author":"Nakayama T","year":"2012","journal-title":"Anticancer Res."},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.10.1755"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12116"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008084"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.11.008"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:08:13Z","timestamp":1695575293000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1002\/ajh.24794"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24794","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,5]]}}}